Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nova Biomedical Corporation currently maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active case is assigned to a distinct examiner and a distinct art unit. This indicates that the company's current prosecution efforts are not dispersed across different technical departments or examiner groups, allowing for a highly focused legal strategy.
The busiest examiner, REGLAS, GEORGIANA C, is responsible for the 1 pending office action. Because this examiner is the point of contact for the company's pending matters, the success of the current prosecution phase is linked to this individual's examination style. It is important to monitor the specific requirements and preferences of this examiner during the response process. The examiner's experience in the Biotechnology & Pharmaceuticals sector will likely influence the scope of the granted claims.
Operating within the distinct art unit simplifies the management of the company's patent filings. There are no conflicting deadlines or procedural differences that often arise when multiple units are involved. The active office action represents the current extent of the company's active interaction with the patent office, providing a clear and manageable objective for the prosecution team.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGLAS, GEORGIANA C | 1 | 37.7% | +36.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767143 | COAGULATION ASSAY APPARATUS AND METHODS THEREOF | REGLAS, GEORGIANA C | 9d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767143 | COAGULATION ASSAY APPARATUS AND METHODS THEREOF | REGLAS, GEORGIANA C | 9d overdue |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17767143 | COAGULATION ASSAY APPARATUS AND METHODS THEREOF | REGLAS, GEORGIANA C | 1651 | §103§112 | Non-Final OA | 9d overdue | Pending | Apr 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial